26 Jun 2018 – PBTZ169 has been named Macozinone. Read more here.
28 Mar 2018 – The phase Ia clinical trial with PBTZ169 is completed and the collected safety data, as well as pharmacokinetic and pharmacodynamic parameters, are being analyzed.
16 Mar 2018 – The first three investigation panels of the Phase Ia clinical trial have been successfully completed. The fourth and final panel has started and healthy male volunteer recruitment is complete.
01 Jan 2018 – Dr. Stewart Cole, Chair of the iM4TB Foundation board and co-founder named head of illustrious Institut Pasteur
01 Jan 2018 – The Year in Review, what happened at iM4TB in 2017